Theravance CEO Rick Winningham said during a presentation at the Credit Suisse Annual Health Care Conference in Scottsdale, Arizona on 13 November that the company will discontinue development of TD-9855 in the treatment of attention-deficit/hyperactivity disorder (ADHD), because the drug did not meet the primary efficacy endpoint in a placebo-controlled Phase II clinical trial.
South San Francisco-based Theravance reported Mr Winningham's comments on TD-9855 disclosure in a US Securities and Exchange Commission (SEC) filing...